In connection with the separation of Becton, Dickinson and Company's (“BD”) diabetes care business (the “Separation”) through the distribution of 100% of the outstanding shares of common stock, par value $0.01 per share, of Embecta Corp. (“embecta”) to BD's stockholders of record as of the close of business on March 22, 2022 (the “Distribution”), each of Claire Pomeroy, MD and David F. Melcher has resigned as directors of BD, in each case effective as of April 1, 2022, in connection with the completion of the Separation and the Distribution and their appointment to the board of directors of embecta.